Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 3/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171520 | 0.83 | ACP3 (0.46) | ACP3GABBR2GABBR1FFAR1SRC | |
| SCHEMBL30481366 | 0.82 | ACP3 (0.40) | ACP3ALDH1A1SRCANPEP | |
| SCHEMBL2173897 | 0.81 | ACP3 (0.45) | ACP3ALDH1A1SRCANPEP | |
| SCHEMBL2171241 | 0.81 | ACP3 (0.44) | ACP3GABBR2GABBR1FFAR1SRC | |
| SCHEMBL2173719 | 0.80 | ACP3 (0.46) | ACP3GABBR2GABBR1FFAR1SRC | |
| SCHEMBL2352708 | 0.79 | ACP3 (0.44) | ACP3ALDH1A1ANPEP | |
| SCHEMBL11297322 | 0.79 | ACP3 (0.61) | ACP3GABBR2GABBR1SRCCYP2C19 | |
| SCHEMBL30481399 | 0.79 | ACP3 (0.40) | ACP3ALDH1A1SRCANPEP | |
| SCHEMBL2170906 | 0.78 | TSHR (0.43) | ACP3 | |
| SCHEMBL2170901 | 0.76 | CYP2D6 (0.62) | ACP3GABBR2GABBR1ALDH1A1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2352740-B1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLIC ACID DERIVATIVES AND USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2014-09-24 | — | — | EP | disclosed |
| US-8735477-B2 | Method for producing dialkylphosphinic acids and esters and salts thereof by means of acrylnitriles and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2014-05-27 | — | — | US | disclosed |
| US-8664418-B2 | Method for producing dialkylphosphinic acids and esters and salts thereof by means of acrylic acid derivatives and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2014-03-04 | — | — | US | disclosed |
| EP-2346885-B1 | METHOD FOR PRODUCING MONO-CARBOXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS/ACROLEINS AND USE THEREOF | CLARIANT INT LTD (CH) | 2013-08-28 | — | — | EP | disclosed |
| EP-2367833-B1 | METHOD FOR PRODUCING MONO-CARBOXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLNITRILES AND USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2013-08-28 | — | — | EP | disclosed |
| US-20110237720-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Vinyl Compounds and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-29 | — | — | US | disclosed |
| EP-2367833-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLNITRILES AND USE THEREOF | Clariant Finance (BVI) Limited (VG) | 2011-09-28 | — | — | EP | disclosed |
| US-20110213052-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylic Acid Derivatives and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| US-20110213059-A1 | Method for Producing Mono-Carboxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by means of Vinylenes-Nitriles and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| EP-2352740-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLIC ACID DERIVATIVES AND USE THEREOF | Clariant Finance (BVI) Limited (VG) | 2011-08-10 | — | — | EP | disclosed |
| EP-2352738-A1 | METHOD FOR PRODUCING MONO-CARBOXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF VINYLENES/NITRILES AND USE THEREOF | Clariant International Ltd. (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2352737-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF VINYL COMPOUNDS AND USE THEREOF | Clariant International Ltd. (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2346885-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS/ACROLEINS AND USE THEREOF | Clariant International Ltd. (CH) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010051888-A1 | METHOD FOR PRODUCING MONO-CARBOXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF VINYLENES/NITRILES AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010051883-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS/ACROLEINS AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010051893-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLIC ACID DERIVATIVES AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010051887-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF VINYL COMPOUNDS AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010051891-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLNITRILES AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213059-A1 | Method for Producing Mono-Carboxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by means of Vinylenes-Nitriles and Use Thereof | ACSL3, ACSL1, ACSL6 | ACP3 1914/4885GABBR2 2078/4885GABBR1 2409/4885 |
| US-20110237720-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Vinyl Compounds and Use Thereof | ACSL3, ACSL6, ACSL1 | ACP3 1300/4885GABBR2 2460/4885GABBR1 3123/4885 |
| US-20110213052-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylic Acid Derivatives and Use Thereof | ACSL3, HAO2, AOC3 | ACP3 526/4885GABBR2 1729/4885GABBR1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.